Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Bets Big on Meningitis:Wall Street Awaits Blockbuster Vaccine Franchise

This article was originally published in RPM Report

Executive Summary

Two years after shaking up the vaccine field with its big entry-acquisition of Chiron, Novartis AG has identified a make-or-break pair of projects in the meningitis area. The meningitis vaccines will determine whether the Novartis bet on vaccines will turn into a smart long-term diversification or a low-return move into an unfamiliar and unfriendly segment of health care.

You may also be interested in...



Cervarix: Two Years Late, But In for the Duration

GlaxoSmithKline has encountered numerous hurdles trying to get its HPV vaccine onto the market to compete in the US against Merck’s Gardasil. GSK appears fi nally on the verge of completing the long process. The question for GSK—and the rest of the vaccine business—is whether the company has created the case for a strong product differentiation for Cervarix versus Gardasil. If it has, it will trigger a new era of vaccine marketing and product development.

Cervarix: Two Years Late, But In for the Duration

GlaxoSmithKline has encountered numerous hurdles trying to get its HPV vaccine onto the market to compete in the US against Merck’s Gardasil. GSK appears fi nally on the verge of completing the long process. The question for GSK—and the rest of the vaccine business—is whether the company has created the case for a strong product differentiation for Cervarix versus Gardasil. If it has, it will trigger a new era of vaccine marketing and product development.

Sticking Point: Novartis Menveo Vaccine Faces Delay Over FDA Request For Info

Although only a few months are at stake, this is the second setback this year for the product, which Novartis hopes will validate its vaccine investments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel